Heart drug study for rare lung disease stopped early
NCT ID NCT04954742
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This study looked at whether the drug riociguat could reduce the size of the right side of the heart in people with two types of high blood pressure in the lungs (pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension). The study planned to enroll 30 adults and measure heart changes using ultrasound. However, the study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre for Pulmonary Hypertension at the Thoraxklinik Heidelberg, Heidelberg University Hospital
Heidelberg, 69126, Germany
Conditions
Explore the condition pages connected to this study.